West Pharmaceutical Services, Inc. (WST) Stock Score, Valuation & Financial Research

West Pharmaceutical Services, Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 43/100.

Quick answer for WST

West Pharmaceutical Services, Inc. currently has a Wall Street Score of 43/100. The stored market price is $346.23. Its financial score is 56/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.

What West Pharmaceutical Services, Inc. does

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary se

WST financial snapshot

Wall Street Score:
43/100
Current price:
$346.23
Market capitalization:
$24.37B
Revenue:
$3.33B
Net income:
$564.9M
Free cash flow:
$468.9M
Cash:
$435.8M
Total debt:
$312.1M
EPS:
6.83
P/E ratio:
50.7x
Financial score:
56/100
Valuation score:
0/100
Revenue score:
20/100

What stands out

  • Reported year-over-year revenue growth is +0.1%.
  • Free cash flow is $468.9M, showing positive cash generation.
  • The balance sheet shows $435.8M of cash versus $312.1M of total debt, leaving more cash than debt.

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 56/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-07-24.

How to research WST

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.